Eaton Vance Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $393K | Sell |
15,641
-8
| -0.1% | -$201 | ﹤0.01% | 1382 |
|
|
2022
Q2 | $476K | Sell |
15,649
-12,152
| -44% | -$370K | ﹤0.01% | 1380 |
|
|
2022
Q1 | $911K | Buy |
27,801
+12,152
| +78% | +$398K | ﹤0.01% | 1388 |
|
|
2021
Q4 | $413K | Hold |
15,649
| – | – | ﹤0.01% | 1368 |
|
|
2021
Q3 | $1.57M | Hold |
15,649
| – | – | ﹤0.01% | 986 |
|
|
2021
Q2 | $2.22M | Sell |
15,649
-277
| -2% | -$39.2K | ﹤0.01% | 988 |
|
|
2021
Q1 | $1.59M | Buy |
15,926
+285
| +2% | +$28.4K | ﹤0.01% | 1025 |
|
|
2020
Q4 | $1.93M | Sell |
15,641
-18
| -0.1% | -$2.23K | ﹤0.01% | 937 |
|
|
2020
Q3 | $1.53M | Hold |
15,659
| – | – | ﹤0.01% | 903 |
|
|
2020
Q2 | $2.44M | Buy |
15,659
+18
| +0.1% | +$2.81K | 0.01% | 765 |
|
|
2020
Q1 | $2.26M | Hold |
15,641
| – | – | 0.01% | 735 |
|
|
2019
Q4 | $3.2M | Buy |
15,641
+4,694
| +43% | +$959K | 0.01% | 731 |
|
|
2019
Q3 | $879K | Hold |
10,947
| – | – | ﹤0.01% | 1001 |
|
|
2019
Q2 | $1.03M | Buy |
+10,947
| New | +$1.03M | ﹤0.01% | 950 |
|